Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]MNI-777 PET Imaging in Tauopathies
NCT02103894Phase 1Completed
- Sponsor
- Molecular NeuroImaging
- Start
- Feb 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of flortaucipir in Alzheimer's disease (AD), Parkinson's disease (PD), chronic traumatic encephalopathy (CTE) and 3 more, sponsored by Molecular NeuroImaging. Primary endpoint: Brain uptake of [18F]T807 ([18F]MNI-777) at 2 years. Started Feb 2014; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)chronic traumatic encephalopathy (CTE)progressive supranuclear palsy (PSP)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT02103894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103894.